The agent fetched the homepage, About page, and a product page, and produced a thorough explanation of NOVARA's products, pricing, audience, and several internal inconsistencies, all drawn from the site. The site was navigable through visible links, though it offered no competitor comparisons, clinical evidence, or manufacturer details, so the 'alternatives' part of the task could only be answered as 'not addressed.'

• ›Homepage linked directly to About and product pages, so the agent reached all core content by following visible navigation rather than guessing URLs.
• ›Product pages exposed full ingredient lists, dosing, and disclaimers in fetchable text, letting the agent verify claims rather than infer them.
• ›The site contains multiple internal contradictions (MRP ₹699 vs ₹1,499, 1–2 capsule dosing vs 1 per serving, 10 reviews claimed vs 6 shown) that a human reader would struggle to reconcile without careful reading.
• ›Regulatory framing is inconsistent: 'Not for medicinal use' labels coexist with 'Unani Proprietary Medicine' classification and health-effect benefit tags.
• ›The site provides no comparative or competitive positioning, so the 'how it differs from alternatives' question could not be answered from the site itself.